Homozygous familial hypercholesterolaemia (HoFH) is a disorder affecting low-density lipoprotein (LDL) receptor genes. Patients typically have a triad of elevated LDL-cholesterol (LDL-C), xanthomatosis and premature atherosclerotic cardiovascular disease. Our patient, a preteen boy, presented with signs of hypertensive encephalopathy. Physical examination showed arcus cornealis, planar xanthomas and tuberous xanthomas. After appropriate investigations, a direct aetiology of the hypertension could not be elucidated; however, our patient's hypertension resolved with the reduction in serum lipid levels. β-hydroxy β-methylglutaryl coenzyme A reductase and cholesterol absorption inhibitors were administered as first-line treatment. A significant proportion of patients with HoFH continue to have elevated LDL-C levels, thereby requiring second-line agents, such as proprotein convertase subtilisin/kexin type inhibitors (evolocumab), microsomal triglyceride transfer protein inhibitors (lomitapide) and angiopoietin-like protein inhibitors (evinacumab). This case report aimed to raise awareness among paediatricians to consider HoFH as a possible aetiology in a child presenting with hypertension and suggestive physical findings.
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Global Year
- Pain Management, Research and Education in Low- and Middle-Income Settings
- Sex and Gender Disparities in Pain
- Integrative Pain Care
- Translating Pain Knowledge to Practice
- Back Pain
- Prevention of Pain
- Pain in the Most Vulnerable
- Pain Education
- Joint Pain
- Pain After Surgery
- Global Year Campaign Archives
- My Letter to Pain
- IASP Statements
- ICD-11 Pain Classification
- Global Alliance of Partners for Pain Advocacy (GAPPA)
- National, Regional, and Global Pain Initiatives
- International Pain Summit
- Pain Awareness Month
- Global Year
- Careers
- About
- For Pain Patients and Professionals